Pharmacological and pharmacokinetic properties of lanthipeptides undergoing clinical studies

2017 ◽  
Vol 39 (4) ◽  
pp. 473-482 ◽  
Author(s):  
Elvis Legala Ongey ◽  
Hüseyin Yassi ◽  
Stephan Pflugmacher ◽  
Peter Neubauer
Keyword(s):  
Clinical Studies ◽  
Pharmacokinetic Properties

Continuous Infusion of Naloxone in the Treatment of Narcotic Overdose

1981 ◽  
Vol 15 (12) ◽  
pp. 945-950 ◽  
Author(s):  
J. Chris Bradberry ◽  
Marsha A. Raebel
Keyword(s):  
Continuous Infusion ◽  
Intravenous Administration ◽  
Clinical Studies ◽  
Case Reports ◽  
Mode Of Administration ◽  
Pharmacokinetic Properties ◽  
Infusion Method

This paper describes case reports and pharmacokinetic information regarding the continuous intravenous administration of naloxone in treatment of narcotic overdose. Continuous naloxone infusion has been used successfully in acutely narcotized patients, and a review of the pharmacodynamic and pharmacokinetic properties of naloxone indicate the reasons for this mode of administration. Summaries of clinical studies in support of the infusion method are given. A naloxone protocol is outlined.

Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies

2015 ◽  
Vol 37 (12) ◽  
pp. 2823-2836 ◽  
Author(s):  
Paul Martin ◽  
Stuart Oliver ◽  
Michael Gillen ◽  
Thomas Marbury ◽  
David Millson
Keyword(s):  
Phase I ◽  
Clinical Studies ◽  
Hepatic Impairment ◽  
Pharmacokinetic Properties

scholarly journals In Vitro Activities of Ravuconazole (BMS-207147) against 541 Clinical Isolates of Cryptococcus neoformans

2000 ◽  
Vol 44 (10) ◽  
pp. 2883-2886 ◽  
Author(s):  
T. Yamazumi ◽  
M. A. Pfaller ◽  
S. A. Messer ◽  
A. Houston ◽  
R. J. Hollis ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Infectious Diseases ◽  
Cryptococcus Neoformans ◽  
Clinical Studies ◽  
Clinical Isolates ◽  
Clinical Specimens ◽  
Pharmacokinetic Properties

ABSTRACT The in vitro activities of the new triazole, ravuconazole (BMS-207147), were compared to those of fluconazole and itraconazole against 541 clinical isolates of Cryptococcus neoformans. Isolates were obtained from cerebrospinal fluid (396), blood (116), and miscellaneous clinical specimens (29). Overall, ravuconazole (MIC at which 90% of the isolates are inhibited [MIC90], 0.25 μg/ml) was more active than either itraconazole (MIC90, 0.5 μg/ml) or fluconazole (MIC90, 8 μg/ml). Among the isolates inhibited by ≥16 μg of fluconazole/ml, 90.2% were inhibited by ≤1 μg of ravuconazole/ml. On the basis of our findings and the favorable pharmacokinetic properties of ravuconazole, we suggest that ravuconazole may be useful for the treatment of infectious diseases due to C. neoformans and that further clinical studies to confirm these promising in vitro results are warranted.

scholarly journals The Effectiveness of Ginger in the Prevention of Nausea and Vomiting during Pregnancy and Chemotherapy

2016 ◽  
Vol 11 ◽  
pp. IMI.S36273 ◽  
Author(s):  
Iñaki Lete ◽  
Josέ Alluέ
Keyword(s):  
Adjuvant Treatment ◽  
Clinical Studies ◽  
Zingiber Officinale ◽  
Nausea And Vomiting ◽  
Safe Treatment ◽  
Traditional Remedy ◽  
Pharmacokinetic Properties ◽  
Ancient Times ◽  
Gastrointestinal Complaints ◽  
Preclinical And Clinical Studies

The rhizomes of Zingiber officinale (ginger) have been used since ancient times as a traditional remedy for gastrointestinal complaints. The most active ingredients in ginger are the pungent principles, particularly gingerols and shogaols. Various preclinical and clinical studies have evaluated ginger as an effective and safe treatment for nausea and vomiting in the context of pregnancy and as an adjuvant treatment for chemotherapy-induced nausea and vomiting. Here, we provide an update and analysis of ginger use for the prevention of nausea and vomiting, with a focus on the types and presentations of ginger available. We also examine the pharmacokinetic properties of ginger and highlight the type and posology of ginger and its metabolites.

scholarly journals Erratum to: Pharmacological and pharmacokinetic properties of lanthipeptides undergoing clinical studies

2017 ◽  
Vol 39 (4) ◽  
pp. 483-483 ◽  
Author(s):  
Elvis Legala Ongey ◽  
Hüseyin Yassi ◽  
Stephan Pflugmacher ◽  
Peter Neubauer
Keyword(s):  
Clinical Studies ◽  
Pharmacokinetic Properties

Aminoglycoside Pharmacokinetics: Volume of Distribution in Specific Adult Patient Subgroups

1994 ◽  
Vol 28 (7-8) ◽  
pp. 944-951 ◽  
Author(s):  
William E. Dager
Keyword(s):  
Adult Patient ◽  
Clinical Studies ◽  
Data Extraction ◽  
Volume Of Distribution ◽  
Data Synthesis ◽  
The Past ◽  
Study Selection ◽  
Pharmacokinetic Properties ◽  
Patient Subgroups ◽  
Volumes Of Distribution

OBJECTIVE: To review the published clinical studies reporting volume of distribution for aminoglycosides in patient population subgroups. Controversies in methods used are discussed. DATA SOURCES: National Library of Medicine Medlars, searched using MEDLINE. STUDY SELECTION: Published articles primarily relating to pharmacokinetic properties of aminoglycosides in specific adult patient subgroups published within the past 20 years were included. Pediatric studies were excluded. DATA EXTRACTION: The methodology, assay technique, and results from clinical studies reporting aminoglycoside volume of distribution were evaluated. DATA SYNTHESIS: Clinical studies reporting aminoglycoside volume of distribution subgroups, including the methods by which their results were derived, are tabulated. CONCLUSIONS: The expected aminoglycoside volume of distribution can vary, depending on a patient's clinical presentation. Data presented will allow a more refined initial estimation of volumes of distribution, which may facilitate the achievement of desired aminoglycoside serum concentrations.

Clinical Studies in Human Strongyloidiasis

1950 ◽  
Vol 16 (4) ◽  
pp. 743-756 ◽  
Author(s):  
Charles A. Jones
Keyword(s):  
Clinical Studies

Exneriana – II – The Scientific Legacy of John E. Exner, Jr. 1Part of this paper was presented at the XIXth International Congress of Rorschach and Projective Methods, July 22–26, 2008, Louvain, Belgium.

2008 ◽  
Vol 29 (2) ◽  
pp. 81-107 ◽  
Author(s):  
Anne Andronikof
Keyword(s):  
Clinical Studies ◽  
Experimental Studies ◽  
Scientific Work ◽  
International Congress ◽  
Response Process ◽  
Scientific Legacy ◽  
Projective Test ◽  
Projective Methods ◽  
Comprehensive Picture ◽  
Complex Mechanisms

Based on an analysis of John Exner’s peer-reviewed published work from 1959 to 2007, plus a brief comment for an editorial in Rorschachiana, the author draws a comprehensive picture of the scientific work of this outstanding personality. The article is divided into three sections: (1) the experimental studies on the Rorschach, (2) the clinical studies using the Rorschach, and (3) Exner’s “testament,” which we draw from the last paper he saw published before his death (Exner, 2001/2002). The experimental studies were aimed at better understanding the nature of the test, in particular the respective roles of perception and projection in the response process. These fundamental studies led to a deeper understanding of the complex mechanisms involved in the Rorschach responses and introduced some hypotheses about the intentions of the author of the test. The latter were subsequently confirmed by the preparatory sketches and documents of Hermann Rorschach, which today can be seen at the H. Rorschach Archives and Museum in Bern (Switzerland). Exner’s research has evidenced the notion that the Rorschach is a perceptive-cognitive-projective test.

Sign in / Sign up

Export Citation Format

Share Document